Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., . . . Mills, G. B. (2017). Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med.
استشهاد بنمط شيكاغوSun, Chaoyang, et al. "Rational Combination Therapy With PARP and MEK Inhibitors Capitalizes On Therapeutic Liabilities in RAS Mutant Cancers." Sci Transl Med 2017.
MLA استشهادSun, Chaoyang, et al. "Rational Combination Therapy With PARP and MEK Inhibitors Capitalizes On Therapeutic Liabilities in RAS Mutant Cancers." Sci Transl Med 2017.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.